Results for
selection inventions
To infinity and beyond! The sufficiency requirements for open-ended ranges (T 1977/22)
Reviewed by
Dr Rose Hughes
on
Tuesday, March 04, 2025
Rating:
5
Inventive step of treating a subpopulation of patients in view of prior art reporting a positive phase 3 clinical trial (T 1437/21)
Reviewed by
Dr Rose Hughes
on
Friday, March 29, 2024
Rating:
5
Unambiguous disclosure without patent profanity (T 2171/21)
Reviewed by
Dr Rose Hughes
on
Wednesday, December 20, 2023
Rating:
5
The criteria for the novelty and inventive step of pharmaceutical selection inventions (T 1356/21)
Reviewed by
Dr Rose Hughes
on
Wednesday, December 13, 2023
Rating:
5
Gold Standard test for novelty reigns supreme, even for subranges (T 1688/20)
Reviewed by
Dr Rose Hughes
on
Tuesday, January 17, 2023
Rating:
5
Boards of Appeal back rejection of special criteria for the novelty of purity inventions, but the Guidelines remain out of step (T 0043/18)
Reviewed by
Dr Rose Hughes
on
Tuesday, August 30, 2022
Rating:
5
Does the requirement for a "technical contribution" in a novel selection survive? (if selecting from convergent lists) (T 1621/16)
Reviewed by
Dr Rose Hughes
on
Wednesday, March 25, 2020
Rating:
5
Do we need a referral to the Enlarged Board of Appeal on the novelty of selection inventions?
Reviewed by
Dr Rose Hughes
on
Monday, January 13, 2020
Rating:
5
2019 updates to the EPO Guidelines for Examination - the highlights
Reviewed by
Dr Rose Hughes
on
Sunday, October 13, 2019
Rating:
5